Unicycive Therapeutics (UNCY) Total Liabilities (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Total Liabilities data on file, last reported at $26.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 60.12% year-over-year to $26.7 million; the trailing twelve-month figure through Mar 2026 stood at $26.7 million (up 60.12% YoY), and the FY2025 full-year result was $18.9 million, down 21.86% from the prior year.
• Total Liabilities for Q1 2026 stood at $26.7 million, up from $18.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $30.7 million in Q1 2024 and bottomed at $2.5 million in Q1 2022.
• The 5-year median for Total Liabilities is $16.0 million (2023), against an average of $14.6 million.
• The widest annual swing landed in 2022, when Total Liabilities jumped 607.13%; it then tumbled 45.6% in 2025.
• A 5-year view of Total Liabilities shows it stood at $3.3 million in 2022, then jumped by 448.11% to $18.0 million in 2023, then jumped by 34.65% to $24.2 million in 2024, then fell by 21.86% to $18.9 million in 2025, then soared by 41.0% to $26.7 million in 2026.
• The last three Total Liabilities figures came in at $26.7 million (Q1 2026), $18.9 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.

Peer Comparison